AGP Executive Report
Last update: 26 minutes agoBeijing Biotech-to-Production Push: A Beijing-backed superconducting materials startup in Yizhuang says it’s moving iron-based superconducting tape from lab to mass production, aiming for ~100 km annual capacity by end-2026—an example of China translating research into industrial output with potential spillovers for advanced medical tech. Border Health Surveillance: WHO urged stronger health surveillance and screening systems at Ghana’s border points, warning that mobile populations can accelerate infectious disease spread without fast referral and coordination. Pharma Independence via AI: A commentary argues AI-driven drug discovery and local manufacturing are key to reducing dependence on foreign supply chains, framing medicine access as a national security issue. Big Pharma-China Licensing Wave: Novartis signed a deal up to $7.8B with China’s Abogen for an mRNA autoimmune therapy, highlighting how licensing is becoming the fastest route to replenish pipelines amid patent cliffs. Clinical Trials Acceleration: HHS launched SURPASS to speed drug testing using simulations and digital twins, but critics note missing details like budget and privacy rules. Public Health & Food Safety Context: A separate report flags concerns about pesticide “chemical colonisation” and health impacts tied to banned molecules exported from Europe to the Global South.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
